Publication details

Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study 'Prague 19'

Authors

KOČKA Viktor MALÝ Martin TOUŠEK Petr BUDĚŠÍNSKÝ Tomas LISA Libor PRODANOV Petko JARKOVSKÝ Jiří WIDIMSKÝ Petr

Year of publication 2014
Type Article in Periodical
Magazine / Source European heart journal
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.1093/eurheartj/eht545
Field Cardiovascular diseases incl. cardiosurgery
Keywords Bioresorbable vascular scaffold; Biodegradable stent; Acute myocardial infarction; Primary PCI; Optical coherence tomography
Description Bioresorbable vascular scaffolds (BVSs) have been studied in chronic coronary artery disease, but not in acute ST-segment elevation myocardial infarction (STEMI). This prospective multicentre study analysed the feasibility and safety of BVS implantation during primary percutaneous coronary intervention (p-PCI) in STEMI. Methods and results Bioresorbable vascular scaffold implantation became the default strategy for all consecutive STEMI patients between 15 December 2012 and 30 August 2013. A total of 142 patients underwent p-PCI; 41 of them (28.9%) fulfilled the inclusion/exclusion criteria for BVS implantation. The BVS device success was 98%, thrombolysis in myocardial infarction 3 flow was restored in 95% of patients, and acute scaffold recoil was 9.7%. An optical coherence tomography (OCT) substudy (21 patients) demonstrated excellent procedural results with only a 1.1% rate of scaffold strut malapposition. Edge dissections were present in a 38% of patients, but were small and clinically silent. Reference vessel diameter measured by quantitative coronary angiography was significantly lower than that measured by OCT by 0.29 (+/-0.56) mm, P = 0.028. Clinical outcomes were compared between BVS group and Control group; the latter was formed by patients who had implanted metallic stent and were in Killip Class I or II. Combined clinical endpoint was defined as death, myocardial infarction, or target vessel revascularization. Event-free survival was the same in both groups; 95% for BVS and 93% for Control group, P = 0.674. Conclusion Bioresorbable vascular scaffold implantation in acute STEMI is feasible and safe. The procedural results evaluated by angiography and OCT are excellent. The early clinical results are encouraging.

You are running an old browser version. We recommend updating your browser to its latest version.

More info